KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBT Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBT Margin for 18 consecutive years, with 23.05% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin fell 683.0% year-over-year to 23.05%; the TTM value through Mar 2026 reached 34.56%, down 82.0%, while the annual FY2025 figure was 36.47%, 281.0% up from the prior year.
  • EBT Margin hit 23.05% in Q1 2026 for Regeneron Pharmaceuticals, down from 26.87% in the prior quarter.
  • Across five years, EBT Margin topped out at 2122.2% in Q1 2022 and bottomed at 22.28% in Q1 2024.
  • Average EBT Margin over 5 years is 233.03%, with a median of 33.71% recorded in 2022.
  • Year-over-year, EBT Margin skyrocketed 207265bps in 2022 and then plummeted -209507bps in 2023.
  • Regeneron Pharmaceuticals' EBT Margin stood at 1324.7% in 2022, then plummeted by -97bps to 33.42% in 2023, then decreased by -24bps to 25.29% in 2024, then grew by 6bps to 26.87% in 2025, then decreased by -14bps to 23.05% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 23.05%, 26.87%, and 46.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.